Wanqiong Li

Shenzhen, 518107, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

An oral vaccine based on stable peptide-chitosan conjugate targeting DEC-205 for cancer immunotherapy.

An oral vaccine based on stable peptide-chitosan conjugate targeting DEC-205 for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: August 07, 2025

Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy.

Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy.

Journal: Cell reports. Medicine

Published: June 02, 2025

Development of a Cascade-Targeting Oral Vaccine via Glycoprotein 2 on Intestinal Microfold Cells for Cancer Immunotherapy.

Development of a Cascade-Targeting Oral Vaccine via Glycoprotein 2 on Intestinal Microfold Cells for Cancer Immunotherapy.

Journal: Nano letters

Published: February 24, 2025

DON-Loaded Nanodrug-T Cell Conjugates With PD-L1 Blockade for Solid Tumor Therapy.

DON-Loaded Nanodrug-T Cell Conjugates With PD-L1 Blockade for Solid Tumor Therapy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: January 28, 2025

VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis.

VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: December 18, 2024

Self-assembled Palmitic Acid-modified Thymopentin Functions as a Delivery System of Nanovaccine for Cancer Immunotherapy.

Self-assembled Palmitic Acid-modified Thymopentin Functions as a Delivery System of Nanovaccine for Cancer Immunotherapy.

Journal: Chembiochem : a European journal of chemical biology

Published: October 17, 2024

Chidamide functions as a VISTA/PSGL-1 blocker for cancer immunotherapy.

Chidamide functions as a VISTA/PSGL-1 blocker for cancer immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: October 08, 2024

A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy.

A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy.

Journal: Nature communications

Published: July 05, 2024

Fish oil-based microemulsion can efficiently deliver oral peptide blocking PD-1/PD-L1 and simultaneously induce ferroptosis for cancer immunotherapy.

Fish oil-based microemulsion can efficiently deliver oral peptide blocking PD-1/PD-L1 and simultaneously induce ferroptosis for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: April 07, 2023

Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.

Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.

Journal: Science China. Life sciences

Published: December 20, 2022

Dietary-Polysaccharide-Modified Fish-Oil-Based Double Emulsion as a Functional Colloidal Formulation for Oral Drug Delivery.

Dietary-Polysaccharide-Modified Fish-Oil-Based Double Emulsion as a Functional Colloidal Formulation for Oral Drug Delivery.

Journal: Pharmaceutics

Published: November 05, 2022

Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression.

Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression.

Journal: Journal for immunotherapy of cancer

Published: October 10, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026